S Palmer

Summary

Affiliation: National Cancer Institute
Country: USA

Publications

  1. ncbi request reprint Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance
    S Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS Res Hum Retroviruses 17:1167-73. 2001
  2. pmc Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 105:3879-84. 2008
  3. pmc Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission
    S Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 103:7094-9. 2006
  4. ncbi request reprint Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 20:701-10. 2006
  5. pmc Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 43:406-13. 2005
  6. pmc Reverse transcriptase and protease sequence evolution in two HIV-1-infected couples
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Acquir Immune Defic Syndr 31:285-90. 2002
  7. pmc New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Clin Microbiol 41:4531-6. 2003
  8. pmc Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals
    M Kearney
    HIV Drug Resistance Program, National Cancer Institute at Frederick, 1050 Boyles Street, Building 535, Room 109, Frederick, MD 21702 1201, USA
    J Virol 83:2715-27. 2009
  9. pmc Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
  10. doi request reprint Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
    Nancy M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 22:1131-5. 2008

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance
    S Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS Res Hum Retroviruses 17:1167-73. 2001
    ..These in vitro susceptibility results suggest that tenofovir DF may be active in vivo against HIV-1 with nucleoside resistance as well as against HIV-1 with non-B subtypes...
  2. pmc Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 105:3879-84. 2008
    ..These data suggest that low-level persistent viremia appears to arise from at least two cell compartments, one in which viral production decays over time and a second in which viral production remains stable for at least 7 years...
  3. pmc Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission
    S Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 103:7094-9. 2006
    ..These findings highlight the urgent need for studies assessing the impact of sdNVP on the efficacy of subsequent antiretroviral therapy containing NVP or other nonnucleoside reverse transcriptase inhibitors...
  4. ncbi request reprint Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 20:701-10. 2006
    ..Understanding the selection and decay of drug-resistant HIV-1 variants is important for designing optimal antiretroviral therapy...
  5. pmc Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 43:406-13. 2005
    ..In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis...
  6. pmc Reverse transcriptase and protease sequence evolution in two HIV-1-infected couples
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Acquir Immune Defic Syndr 31:285-90. 2002
    ....
  7. pmc New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Clin Microbiol 41:4531-6. 2003
    ....
  8. pmc Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals
    M Kearney
    HIV Drug Resistance Program, National Cancer Institute at Frederick, 1050 Boyles Street, Building 535, Room 109, Frederick, MD 21702 1201, USA
    J Virol 83:2715-27. 2009
    ..These results have important implications for vaccine strategies because they imply that some HLA alleles could be compromised in newly acquired HIV infections...
  9. pmc Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
    ..Mutations remained detectable for at least 48 weeks in some subjects...
  10. doi request reprint Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
    Nancy M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 22:1131-5. 2008
    ..Valproic acid and intensified antiretroviral therapy may deplete resting CD4+ T-cell HIV infection. We tested the ability of valproic acid to deplete resting CD4+ T-cell infection in patients receiving standard antiretroviral therapy...
  11. pmc Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase
    Mary Kearney
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 22:497-501. 2008
    ..Failure of antiretroviral therapy may result from the selection of pre-existing, drug-resistant HIV-1 variants, but the frequency and type of such variants have not been defined...
  12. ncbi request reprint Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction
    Daniel E Kaufmann
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Immunol 8:1246-54. 2007
    ..These data, indicating a reversible immunoregulatory pathway selectively associated with CD4(+) T cell dysfunction, provide a potential target for immunotherapy in HIV-infected patients...
  13. pmc Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy
    Zandrea Ambrose
    HIV Drug Resistance Program, National Cancer Institute, Building 535, Room 123, Frederick, MD 21702, USA
    J Virol 81:12145-55. 2007
    ..By contrast, ART effectively suppressed RT-SHIV in 5/6 animals. These data indicate that suboptimal therapy facilitates HIV-1 drug resistance and suggest that this model can be used to investigate persisting viral reservoirs...
  14. pmc ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
    Frank Maldarelli
    HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America
    PLoS Pathog 3:e46. 2007
    ..These data suggest that the persistent viremia on current antiretroviral therapy is derived, at least in part, from long-lived cells that are infected prior to initiation of therapy...
  15. pmc Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance
    Galina N Nikolenko
    Viral Mutation Section and Host Virus Interaction Unit, HIV Drug Resistance Program, and Data Management Services, Inc, National Cancer Institute, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 104:317-22. 2007
    ..These results indicate that mutations in the C-terminal domain of RT significantly enhance clinical NRTI resistance and should be considered in genotypic and phenotypic drug resistance studies...
  16. pmc Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency
    Elias K Halvas
    Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, S818 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, and Children s Hospital of Los Angeles, CA, USA
    J Clin Microbiol 44:2612-4. 2006
    ..1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy...
  17. ncbi request reprint HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization
    John F Vickrey
    Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, 540 E Canfield Avenue, Detroit, MI 48201, USA
    Protein Expr Purif 28:165-72. 2003
    ..Here, we report the expression, purification, and crystallization of clinical isolates of HIV-1 protease that have been characterized to be more than 100 times less susceptible to US FDA approved protease inhibitors...
  18. pmc Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
    Ginger Lehrman
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 753901, USA
    Lancet 366:549-55. 2005
    ..Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells...
  19. pmc Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision
    Galina N Nikolenko
    Viral Mutation Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 102:2093-8. 2005
    ....
  20. pmc In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques
    Zandrea Ambrose
    HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    J Virol 78:13553-61. 2004
    ..Collectively, these results indicate that RT-SHIV(mne) may be a useful model in macaques for the preclinical evaluation of NNRTIs and for studies of the development of drug resistance in vivo...
  21. ncbi request reprint A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Infect Dis 189:1974-82. 2004
    ..Adherence to such a regimen may be problematic for certain patients...
  22. ncbi request reprint Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome
    Qin Yu
    Infectious Disease Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Struct Mol Biol 11:435-42. 2004
    ..We propose that the requirement for ssDNA accounts for the minus-strand mutations, the 5'-->3' graded frequency of deamination and the rare C-->T mutations...